Title:
ANTI-MEEGFR ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/046396
Kind Code:
A1
Abstract:
The present invention relates to an anti-methylated epidermal growth factor receptor (meEGFR) antibody or an antigen-binding fragment thereof, a detection kit, a method for detecting a meEGFR positive cancer, a pharmaceutical composition for treatment of a cancer, a meEGFR-specific chimeric antigen receptor, a nucleic acid encoding the meEGFR-specific chimeric antigen receptor, a meEGFR-specific chimeric antigen receptor expressing cell, an innate cell engager, and an antibody conjugate. The anti-meEGFR antibody or the antigen-binding fragment thereof specifically binds to the meEGFR, and the meEGFR has asymmetric dimethylation modification at R198 and R200 sites; therefore, the anti-meEGFR antibody or the antigen-binding fragment thereof may be used as a detection kit for detecting a meEGFR positive cancer, and can be applied to the treatment of the meEGFR positive cancer.
Inventors:
HUNG MIEN-CHIE (CN)
WANG SHAO-CHUN (CN)
YAMAGUCHI HIROHITO (CN)
HSU JUNG-MAO (CN)
SHEN YI-CHUN (CN)
LI HONG-WEI (CN)
LIN YOU-ZHE (CN)
WANG SHAO-CHUN (CN)
YAMAGUCHI HIROHITO (CN)
HSU JUNG-MAO (CN)
SHEN YI-CHUN (CN)
LI HONG-WEI (CN)
LIN YOU-ZHE (CN)
Application Number:
PCT/CN2023/115936
Publication Date:
March 07, 2024
Filing Date:
August 30, 2023
Export Citation:
Assignee:
HUNG MIEN CHIE (CN)
International Classes:
C07K16/28; A61K9/00; A61K39/395; C07K16/30; C07K16/32; C12N15/09; G01N33/574; G01N33/74
Domestic Patent References:
| WO2013163631A2 | 2013-10-31 |
Foreign References:
| US20160279240A1 | 2016-09-29 | |||
| US20110200595A1 | 2011-08-18 | |||
| US20170190787A1 | 2017-07-06 | |||
| US20170314079A1 | 2017-11-02 | |||
| US20200087405A1 | 2020-03-19 | |||
| CN103781494A | 2014-05-07 |
Attorney, Agent or Firm:
LECOME INTELLECTUAL PROPERTY AGENT LTD. (CN)
Download PDF: